Results 271 to 280 of about 71,240 (317)

Hepatitis B e Antigen — The Dangerous Endgame of Hepatitis B

New England Journal of Medicine, 2002
The external pernicious influences of wind and dampness cause liver Qi to stagnate, and excess damp heat in liver and weakness of spleen Qi result.
T. Jake Liang, Marc Ghany
openaire   +1 more source

THE e ANTIGEN AND VERTICAL TRANSMISSION OF HEPATITIS B SURFACE ANTIGEN

American Journal of Epidemiology, 1977
The relationship of e antigen (eAg) and its antibody (anti-e) to vertical transmission of hepatitis B surface antigen (HBsAg) from chronic asymptomatic HBsAg carrier women to their children was investigated in Taiwan. Sera from 20 of the 62 women studied were positive for eAg (32%); serum from only one woman was positive for anti-e (2%). A total of 85%
R P, Beasley, C, Trepo, C E, Stevens, W, Szmuness   +3 more
openaire   +2 more sources

Hepatitis B e Antigen and Antibody Measured by Radioimmunoassay in Acute Hepatitis B Surface Antigen-Positive Hepatitis

Journal of Infectious Diseases, 1980
The presence of the hepatitis B e antigen (HBeAg) and antibody to HBeAg (anti-HBe) was studied by a solid-phase radioimmunoassay in 70 patients with acute hepatitis positive for hepatitis B surface antigen. HBeAg was found in 15 of 16 patients studied within two weeks after onset of symptoms. In total, 45 patients were found positive for HBeAg.
J, Aldershvile, G G, Frösner, J O, Nielsen, F, Hardt, F, Deinhardt, P, Skinhøj   +5 more
openaire   +2 more sources

Interferon Therapy in Hepatitis B E Antigen-Negative Chronic Hepatitis B

Hepatology, 2003
teristics, making them both less likely to develop progressive liver disease and more tolerant to IFN side effects. The proportion of the responder patients varies according to referral centers and inclusion criteria, but cannot be significant in that the efficacy of IFN treatment still is not proven.
Agostino, Colli, Sara, Massironi, Marco, Anreoletti   +2 more
openaire   +2 more sources

Treatment of hepatitis B e antigen-negative chronic hepatitis B with lamivudine

Journal of Hepatology, 2003
The advent of lamivudine (LAM) has provided an alternative also to the therapy of hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB); management of this disease with alpha-interferon (IFN) has been problematic because of the poor response and high relapse rate of short-term therapies and because of the important side effects associated ...
Mario, Rizzetto, Alfredo, Marzano, Marco, Lagget   +2 more
openaire   +2 more sources

Hepatitis B e antigen and antibody activity in hepatitis B virus infection

The Journal of Pediatrics, 1977
Groups of institutionalized subjects, volunteer blood donors with serologic evidence of asymptomatic hepatitis B virus infection, and patients with acute type B viral hepatitis were studied for the presence of hepatitis B e antigen and antibody in a sequential manner over a period of two to three years.
M L, Tiku, G M, Makhdoomi, K R, Beutner, N, Nath, P L, Ogra   +4 more
openaire   +2 more sources

Occult hepatitis B virus infection with positive hepatitis B e antigen

Clinica Chimica Acta, 2015
Hepatitis B e antigen (HBeAg) is a marker to indicate active replication of hepatitis B virus (HBV). Occult HBV infection (OBI), referred to persistence of HBV DNA in serum and/or liver without detectable serum hepatitis B surface (HBsAg), usually has low HBV DNA levels.
Zhenge, Han, Yong, Liu, Jinshun, Pan, Yongchun, Bi, Jingli, Liu, Yi-Hua, Zhou   +5 more
openaire   +2 more sources

Immunopathogenesis of hepatitis B e antigen negative chronic hepatitis B infection

Antiviral Research, 2001
Hepatitis B e antigen (HBeAg) negative chronic hepatitis B represents currently the predominant form of chronic hepatitis due to the hepatitis B virus (HBV) in several parts of the world. In this review, recent data regarding the process of HBeAg negative HBV strain selection during the course of chronic HBV infection are presented and the potential ...
S J, Hadziyannis, D, Vassilopoulos
openaire   +2 more sources

Determinants for hepatitis B e antigen clearance in chronic type B hepatitis

Liver, 1984
ABSTRACT— A 6‐year (mean 24.5 months) longitudinal study has been undertaken in 237 HBeAg‐positive patients with clinicopathologically verified chronic hepatitis. HBeAg clearance occurred in 74 patients at a rate of 16% per year, and a cumulative probability of 67% at the end of a 5‐year follow‐up.
Y F, Liaw, C M, Chu, M J, Huang, I S, Sheen, C Y, Yang, D Y, Lin   +5 more
openaire   +2 more sources

Discordance of hepatitis B e antigen and hepatitis B viral deoxyribonucleic acid

Journal of Medical Virology, 1990
AbstractSera from 899 hepatitis B surface antigen (HBsAg) carriers from four separate ethnic groups (Caucasian, Australian Aboriginal, Melanesian, and Asian) were studied for their correlation for hepatitis B virus deoxyribonucleic acid (HBV DNA) and hepatitis B e antigen (HBeAg). Discordance, as signified by the absence of HBV DNA despite the presence
Scott, Janet S., Pace, Raymond A., Sheridan, John W., Cooksley, W. Graham   +3 more
openaire   +5 more sources